FAKTOR PENCETUS KETOASIDOSIS DIABETIK PADA PENGGUNA EMPAGLIFLOZIN: TINJAUAN LITERATUR
JHN: Journal of Health and Nursing · 19.11.2026 · 4 (2) · 718-736
DOI: 10.58738/jhn.v4i2.2011 ↗Kurz gefasst
Fachartikel in der Zeitschrift JHN: Journal of Health and Nursing, online erschienen am 19.11.2026. Verfasst von Anisa Amanda Putri und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).
Abstract (Originalsprache)
Euglycemic diabetic ketoacidosis (euDKA) is a rare but life-threatening complication in users of empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor prescribed for type 2 diabetes mellitus (T2DM), where normal or mildly elevated blood glucose levels (
Zitieren
APA
Putri, A. A., Sholih, M. G., & Sakinah, M. N. (2026). FAKTOR PENCETUS KETOASIDOSIS DIABETIK PADA PENGGUNA EMPAGLIFLOZIN: TINJAUAN LITERATUR. JHN: Journal of Health and Nursing, 4(2), 718-736. https://doi.org/10.58738/jhn.v4i2.2011
Vancouver
Putri AA, Sholih MG, Sakinah MN. FAKTOR PENCETUS KETOASIDOSIS DIABETIK PADA PENGGUNA EMPAGLIFLOZIN: TINJAUAN LITERATUR. JHN: Journal of Health and Nursing. 2026;4(2):718-736. doi:10.58738/jhn.v4i2.2011
BibTeX
@article{Putri2026,
author = {Putri, Anisa Amanda and Sholih, Mally Ghinan and Sakinah, Mutiara Nurhalidza},
title = {FAKTOR PENCETUS KETOASIDOSIS DIABETIK PADA PENGGUNA EMPAGLIFLOZIN: TINJAUAN LITERATUR},
journal = {JHN: Journal of Health and Nursing},
year = {2026},
volume = {4},
number = {2},
pages = {718--736},
doi = {10.58738/jhn.v4i2.2011}
}
EUVIMED